Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT9425-23-LCRP-TRA: DOD Lung Cancer, Translational Research Award

Closed Closed August 3, 2023 Opportunity HT9425-23-LCRP-TRA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2023.

• Total funding$7.7 million
• Expected awards5
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY23 LCRP Translational Research Award mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science (bench to bedside and/or bedside to bench). Research applications only in the area of mesothelioma will not be accepted. This mechanism is intended to fund a broad range of translational studies with two different funding levels. The following are general examples, although not all-inclusive, of the type of research projects that would be appropriate to propose under the current program announcement: Funding Level 1: Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts (The Translational Research Award is not intended to support initial mechanistic studies of a new target.) Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trials to improve clinical management of lung cancer and/or define new areas of research Projects that develop endpoints for clinical trials Funding Level 2: Pilot clinical trials where limited clinical testing (e.g., small sample size) of a novel intervention is necessary to inform the next step in the continuum of translational research Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.